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Abstract. Mesenchymal stem cells (MSCs) are clinically 
useful due to their capacity for self-renewal, their immu-
nomodulatory properties and tissue regenerative potential. 
These cells can be isolated from various tissues and exhibit 
different potential for clinical applications according to 
their origin, and thus comparative studies on MSCs from 
different tissues are essential. In this study, we investigated 
the immunophenotype, proliferative potential, multilineage 
differentiation and immunomodulatory capacity of MSCs 
derived from different tissue sources, namely bone marrow, 
adipose tissue, the placenta and umbilical cord blood. The 
gene expression profiles of stemness-related genes [octamer-
binding transcription factor 4 (OCT4), sex determining 
region Y-box (SOX)2, MYC, Krüppel-like factor 4 (KLF4), 
NANOG, LIN28 and REX1] and lineage-related and differen-
tiation stage-related genes [B4GALNT1 (GM2/GS2 synthase), 
inhibin, beta A (INHBA), distal-less homeobox 5 (DLX5), 
runt-related transcription factor 2 (RUNX2), proliferator-acti-
vated receptor gamma (PPARG), CCAAT/enhancer-binding 
protein alpha (C/EBPA), bone morphogenetic protein 7 (BMP7) 
and SOX9] were compared using RT-PCR. No significant 
differences in growth rate, colony-forming efficiency and 
immunophenotype were observed. Our results demonstrated 
that MSCs derived from bone marrow and adipose tissue shared 
not only in vitro tri-lineage differentiation potential, but also 
gene expression profiles. While there was considerable inter-
donor variation in DLX5 expression between MSCs derived 
from different tissues, its expression appears to be associated 
with the osteogenic potential of MSCs. Bone marrow-derived 
MSCs (BM-MSCs) significantly inhibited allogeneic T cell 
proliferation possibly via the high levels of the immunosup-
pressive cytokines, IL10 and TGFB1. Although MSCs derived 
from different tissues and fibroblasts share many characteris-
tics, some of the marker genes, such as B4GALNT1 and DLX5 
may be useful for the characterization of MSCs derived from 
different tissue sources. Collectively, our results suggest that, 
based on their tri-lineage differentiation potential and immu-
nomodulatory effects, BM-MSCs and adipose tissue-derived 
MSCs (A-MSCs) represent the optimal stem cell source for 
tissue engineering and regenerative medicine.
Introduction
Mesenchymal stem cells (MSCs) are multipotent somatic stem 
cells that have the potential to differentiate into mesodermal and 
even non-mesodermal lineages and are known to produce trophic 
factor for tissue repair/regeneration (1-4). Due to their ease of 
isolation, culture expansion, multipotential differentiation and 
immunomodulatory properties, MSCs have the potential for use 
in regenerative medicine and have therapeutic application (5). 
Indeed, MSCs have been investigated in a number of clinical 
trials for presently untreatable diseases, such as bone and carti-
lage defects, myocardial infarction, stroke, graft-versus-host 
disease (GvHD) and autoimmune diseases (6,7).
Although MSCs were first reported to be derived from bone 
marrow, a number of studies have reported similar cell types in 
a wide range of tissues, e.g., umbilical cord blood, the placenta, 
adipose tissue, amniotic fluid, dental tissue, skin, hair follicles 
and tonsils (8-14). Given the observed clinical efficacy of MSCs 
and a number of comparative analyses of MSCs derived from 
different tissues, it is surprising that so little is known about 
the identity and characteristics of MSCs derived from different 
tissues (15,16). Although the International Society for Cellular 
Therapy (ISCT) proposed the minimal criteria of MSCs in 
2006, this definition is non-specific and fails to address the 
differences between MSCs (derived from different tissues) and 
fibroblasts (17).
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Currently, there is no consensus on the markers that iden-
tify or distinguish MSCs derived from different tissues and 
fibroblasts. Furthermore, a precise characterization of MSCs 
derived from different tissues and their properties relating to 
their therapeutic potential represent an essential requirement 
for the exploitation and development of optimal MSC-based 
therapies, since the biological capacity of MSCs (i.e., immu-
nomodulatory capacity, differentiation potential to a specific 
cell type and endogenous stem cell mobilizing capacity) of one 
tissue may be superior to others.
The aim of the present study was to compare the biological 
characteristics of MSCs originating from different tissues, 
i.e., bone marrow (BM-MSCs), umbilical cord blood (CB-MSCs), 
placenta (P-MSCs) and adipose tissue (A-MSCs), with respect to 
cell morphology, growth rate, immunophenotype, gene expres-
sion profile, immunomodulatory capacity and differentiation 
potential under the same conditions. The characterization of 
MSCs derived from different tissues with identifying molecular 
signatures may prove to be helpful for selecting a suitable source 
for a specified clinical application.
Materials and methods
Cells. Bone marrow samples (from 3 male donors, aged 21, 26 
and 27 years, respectively) were obtained from normal allo-
geneic hematopoietic stem cell donors after obtaining written 
informed consent. Umbilical cord blood was collected in a bag 
with CPDA anticoagulant following delivery (from 3 donor 
babies, 1 male and 2 females). This study was approved by the 
Institutional Review Boards of Severance Hospital (an affiliated 
hospital of Yonsei University Health System, Seoul, Korea). 
The mononuclear cell (MNC) fraction was separated by Ficoll-
Hypaque density gradient centrifugation (Pharmacia Biotech, 
Uppsala, Sweden), and the MSCs were cultured as previously 
described (18). Human dermal fibroblasts (from 3 donors, a 
22 year-old female, 26 year-old female and 31 year-old male) 
were provided by Dr Dong-Wook Kim (Yonsei University 
College of Medicine, Korea). In this study, fibroblasts were 
used as a negative control. Placental- (from 3 donors, 28-, 
32- and 33-year-old females) and adipose tissue-derived MSCs 
(from 3 donors, 34-, 41- and 46-year old females) were kindly 
provided by Dr Ja Young Kwon (Yonsei University College of 
Medicine) and Dr Kyoung Sik Kim (Yonsei University College 
of Medicine), respectively. The isolated MSCs were frozen 
until the cells were used. To permit an exact analysis, all cells 
were used at passage 3-5 and cultured under standardized 
conditions; DMEM-low glucose supplemented with 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (P/S) (all 
from Invitrogen, Carlsbad, CA, USA). The cells were cultured 
at 37˚C with 5% CO2, and the media were replaced every 3 
or 4 days. Over the course of expansion, we examined the 
differences in cell morphology under an inverted phase micro-
scope (Olympus IX-71; Olympus, Tokyo, Japan).
Growth characteristics. To compare the growth characteristics 
of the cells, the growth rate and population doubling time (PDT; 
period of time required for cells to proliferate or grow) were 
measured. All cells were plated at a density of 2x104 cells in 
12-well plates. On days 2 and 4, the cells were harvested and 
counted by Trypan blue staining. The PDT was calculated based 
on a previously reported formula (19). The finite population 
doublings were defined as the cumulative number of serial cell 
passages until the cells reached senescence.
Colony-forming unit-fibroblast (CFU-F) assay. The capacity 
of the cells for self-renewal can be evaluated by CFU-F assay. 
To assess the self-renewal capacity of the cells, 1x103 cells 
at passage 3 were seeded in 100-mm plates (Corning Inc., 
Corning, NY, USA). Following cultivation for 14 days, the cells 
were washed with phosphate-buffered saline (PBS; Invitrogen) 
and stained with 0.5% crystal violet (Sigma-Aldrich, St. Louis, 
MO, USA) for 5 min at room temperature. Stained colonies 
with >50 cells were counted.
Immunophenotyping. The cells were stained with the following 
antibodies: CD14-FITC (555397), CD29-FITC (556048), 
CD31-PE (555446), CD34-FITC (560942), CD44-PE (555479), 
CD45-PE (561866), CD73-PE (550257), CD90-FITC (555595), 
CD105-PE (560839) and CD106-FITC (551146) (all from 
BD Pharmingen, San Diego, CA, USA). Additionally, phyco-
erythrin-conjugated and FITC-conjugated isotype controls 
were applied. The cells were stained with the antibodies for 
20 min at 4˚C. The stained cells were washed with PBS and 
fixed with 1% paraformaldehyde (Biosesang, Seongnam, 
Korea). Subsequently, the labeled cells were analyzed using a 
flow cytometer (Cytomics Flow Cytometer; Beckman Coulter, 
Fullerton, CA, USA).
RNA isolation and RT-PCR. Total RNA was extracted using 
TRIzol reagent (Invitrogen). Standard reverse transcrip-
tion (RT) was performed using transcriptase II (Invitrogen). 
RT-PCR was performed using PCR primers (Bioneer, Daejeon, 
Korea) under the conditions listed in Table I. The glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) level was used as 
an internal control. Human induced pluripotent stem (hiPS) 
cell cDNA was used as a positive control (kindly provided by 
Dr Dong-Wook Kim, Yonsei University College of Medicine). 
The signal intensity of the product was normalized to its 
respective GAPDH signal intensity.
Differentiation assay. To induce osteogenic, adipogenic and 
chondrogenic differentiation, the cells derived from each type 
of tissue were seeded simultaneously in osteogenic induction 
medium, chondrogenic induction medium, and adipogenic 
induction medium (Cambrex, Lonza, MD, USA). The cells 
were then cultured for 3 weeks, and the medium was changed 
every 3 or 4 days. Whenever the medium was changed during 
chondrogenesis, 10 ng/ml transforming growth factor (TGF)-β3 
(Cambrex) was added. After 3 weeks, the cells were analyzed 
for osteogenesis, adipogenesis and chondrogenesis by von Kossa 
staining, Oil Red O staining, and Safranin O staining. The stained 
cells were photographed using a phase microscope (Olympus 
IX-71; Olympus).
T cell proliferation assay. To assess the ability of MSCs to 
suppress T cell proliferation, the MSCs were treated with 
50 ng/ml of mitomycin C (Sigma-Aldrich) for 60 min to inac-
tivate their proliferation. Subsequently, 2x105 cells of human 
peripheral blood MNCs were co-cultured with 2x104 MSCs 
of each type in a 96-well plate. To activate T cells, 10 µg/ml 
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Table I. Primer sets used for RT-PCR.
Gene Primer sequence (5'→3') Annealing temperature (˚C) Product size (bp)
GAPDH Forward: GTGGTCTCCTCTGACTTCAACA
 Reverse: CTCTTCCTCTTGTGCTCTTGCT 62 210
OCT4 Forward: GACAACAATGAGAACCTTCAGGAGA
 Reverse: TTCTGGCGCCGGTTACAGAACCA 62 218
SOX2 Forward: AACCAAGACGCTCATGAAGAAG
 Reverse: GCGAGTAGGACATGCTGTAGGT 62 341
c-Myc Forward: TCGGATTCTCTGCTCTCCTC
 Reverse: CGCCTCTTGACATTCTCCTC 62 413
KLF4 Forward: ATTCTCTCCAATTCGCTGACCC
 Reverse: TTCAGCACGAACTTGCCCAT 62 376
NANOG Forward: ATAGCAATGGTGTGACGCAG
 Reverse: GATTGTTCCAGGATTGGGTG 62 219
REX1 Forward: CTGAAGAAACGGGCAAAGAC
 Reverse: GAACATTCAAGGGAGCTTGC 58 344
LIN28 Forward: GCTCCGTGTCCAACCAGCAG
 Reverse: TTTCCTTTTGGCCGCCTCTC 58 376
GD2 synthase Forward: CCAACTCAACAGGCAACTAC
 Reverse: GATCATAACGGAGGAAGGTC 59 230
DLX5 Forward: ACCATCCGTCTCAGGAATCG
 Reverse: ACCTTCTCTGTAATGCGGCC 60 384
CBFA1 Forward: TTGCAGCCATAAGAGGGTAG
 Reverse: GTCACTTTCTTGGAGCAGGA 58 470
PPARG Forward: TCTCTCCGTAATGGAAGACC
 Reverse: GCATTATGAGACATCCCCAC 55 474
C/EBPA Forward: CCAAGAAGTCGGTGGACAAGAA
 Reverse: TCATTGTCACTGGTCAGCTCCA 62 145
BMP7 Forward: CCAACGTCATCCTGAAGAAATAC
 Reverse: GCTTGTAGGATCTTGTTCATTGG 60 271
SOX9 Forward: GGTTGTTGGAGCTTTCCTCA
 Reverse: TAGCCTCCCTCACTCCAAGA 61 400
HLA-ABC Forward: CAGATACCTGGAGAACGG
 Reverse: TGGCCTCATGGTCAGAGA 56   96
HLA-DR Forward: CCCCACAGCACGTTTCTTG
 Reverse: CCGCTGCACTGTGAAGCTCT 60 274
HLA-G Forward: GCGGCTACTACAACCAGAGC
 Reverse: GCACATGGCACGTGTATCTC 58 900
IL10 Forward: ACCTGGTAGAAGTGATGCCCCAGGCA
 Reverse: CTATGCAGTTGATGAAGATGTCAA 58 237
TNFAIP6 Forward: GGTGTGTACCACAGAGAAGCA
 Reverse: GGGTTGTAGCAATAGGCATCC 60 284
TSG-6 Forward: GGTGTGTACCACAGAGAAGCA
 Reverse: GGGTTGTAGCAATAGGCATCC 60 284
IL6 Forward: ATGAACTCCTTCTCCACAAGC
 Reverse: GTTTCTGCCAGTGCCTCTTTG 60 264
TGFB1 Forward: GAGGTGACCTGGCCACCATT
 Reverse: TCCGCAAGGACCTCGGCTGG 55 194
INHBA Forward: GATGTACCCAACTCTCAGCCA
 Reverse: GCCGATGTCCTTGAAACTGAC 55 866
SOX2, sex determining region Y-box 2; DLX5, distal-less homeobox 5; C/EBPA, CCAAT/enhancer-binding protein alpha; BMP7, bone morpho-
genetic protein 7; IL, interleukin ; TGFB1, transforming growth factor beta 1. OCT4, octamer-binding transcription factor 4; KLF4, Krüppel-like 
factor 4; DLX5, distal-less homeobox 5; CBFA1, core-binding factor alpha (1); PPARG, proliferator-activated receptor gamma; TNFAIP6, 
tumor necrosis factor, alpha-induced protein 6; TSG-6, tumor necrosis factor-stimulated gene 6 (TSG-6); IHHBA, Activin A, inhibin beta A.
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phytohaemagglutinin (PHA; Sigma-Aldrich) was applied for 
72 h. To examine the inhibition of T cells, a BrdU cell prolif-
eration assay (Millipore, Billerica, MA, USA) was performed 
according to the manufacturer's instructions. Activated T cells 
alone without MSCs were used as a positive control.
Statistical analysis. Quantitative data are expressed as the 
means ± SD. All statistical comparisons between groups were 
performed by one-way analysis of variance (ANOVA) with 
post hoc Bonferroni corrections. A p-value <0.05 was consid-
ered to indicate a statistically significant difference.
Results
Growth characteristics of MSCs derived from different tissues. 
All MSCs and fibroblasts exhibited similar growth proper-
ties on day 2. However, of the MSCs derived from different 
tissues, the P-MSCs displayed the highest proliferative capacity 
between days 2 and 4 (Fig. 1A), as they had the lowest PDT. 
Although the P-MSCs showed a slight increase in growth 
compared to the controls (shown by the decrease in the PDT), 
the differences in population doubling time between the tested 
cells were not statistically significant. Although the cells were 
isolated from different tissues, we did not find any differ-
ences in our morphological examination (data not shown). To 
determine the maximum proliferative capacity, all cell types 
were serially passaged until they displayed replicative senes-
cence with a loss of proliferation. Of the MSCs derived from 
different tissues, the P-MSCs could withstand longer periods of 
culture, whereas the BM-, CB- and A-MSCs exhibited a similar 
maximum culture period (Fig. 1B). The CFU-F assay was used 
to examine the self-renewal capacity of the cells. Although the 
fibroblasts and P-MSCs exhibited better growth characteristics 
than the other cells, there were no significant differences in 
the number of CFU-Fs following cell seeding at 1x103 cells in 
100-mm plates after 14 days (Fig. 1C). The BM- and CB-MSCs 
displayed a higher self-renewal capacity regardless of growth 
rate, although the differences were not significant.
Figure 1. Growth characteristics and stemness marker expression of human mesenchymal stem cells (MSCs) derived from different tissues. (A) Growth kinetics. 
Population doubling time (PDT, measured in hours) was determined at each subcultivation. MSCs derived from bone marrow (BM-MSCs), umbilical cord 
blood (CB-MSCs), the placenta (P-MSCs) and adipose tissue (A-MSCs) that were cultured under identical conditions. (B) Long-term expandability. The finite 
population doublings, defined as the total number of serial cell passaging before reaching replicative senescence. **p<0.01. (C) Clonogenic capacity was measured 
by colony forming unit-fibroblast (CFU-F) assay. The results (A-C) were obtained from 3 independent donors and are represented as the means ± SD. (D) Stemness 
marker expression in MSCs derived from different tissues. RT-PCR analysis for pluripotency markers in MSCs derived from bone marrow, umbilical cord blood, 
the placenta and adipose tissue compared to induced pluripotent stem (iPS) cell and fibroblasts (F). RT(-) denotes the absence of reverse transcriptase as a control. 
One representative of 3 independent experiments is shown.
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In order to identify the molecular signature, we examined 
the expression of stemness markers in the MSCs derived from 
different tissues (Fig. 1D). The octamer-binding transcription 
factor 4 (OCT4) gene was not detected in any of the MSCs, 
or the fibroblasts. Sex determining region Y-box 2 (SOX2) 
was only expressed in the BM-MSCs; NANOG was detected 
in the BM-, P- and A-MSCs. Compared to the hiPS cells, 
the expression of SOX2 and NANOG was much lower in the 
BM-MSCs. Krüppel-like factor 4 (KLF4) was expressed in 
all types of cells and fibroblasts, whereas MYC was expressed 
in all cells apart from the fibroblasts and P-MSCs. Activin A 
[inhibin, beta A (INHBA)] was strongly detected in the BM- 
and A-MSCs, as compared to the fibroblasts and MSCs derived 
from other tissues. Compared to the hiPS cells, MYC, KLF4 
and INHBA expression was much stronger in the other MSCs 
tested. In the A-MSCs we noted a basal expression of LIN28 
and REX1, which was much lower than that expressed in 
the hiPS cells. These results suggest that BM- and A-MSCs 
possess the highest capacity for self-renewal and differentiation 
potential in multiple lineages, whereas P-MSCs have the least 
functionality as stem cells of those which were tested.
Immunophenotype and differentiation potential. Flow cyto-
metric analysis was performed with the MSCs derived from 
different tissues, and we revealed that all cell types displayed 
similar immunophenotypic patterns. The cells were negative 
for CD14, CD31, CD34, CD45 and CD106, which are known 
markers of hematopoietic and endothelial cells, whereas 
the MSCs were positive for CD29, CD44, CD73, CD90 and 
CD105, which are known markers of MSCs. Positive MSC 
markers were expressed in all of the cell types, even in fibro-
blasts (Table II). These results confirm that cells from diverse 
sources express MSC surface markers, as defined by the ISCT. 
However, the expression of CD90, a typical MSC marker, was 
less obvious in the P-MSCs than in the other cells.
To investigate the differentiation potential of the MSCs, 
the cells were subjected to osteogenic, adipogenic and chon-
drogenic differentiation (Fig. 2A). Osteogenic differentiation, 
which was evaluated by calcium deposition and von Kossa 
staining, was evident in the BM- and A-MSCs, whereas the 
other MSCs did not differentiate into osteoblasts under osteo-
genic induction. No osteogenic differentiation was induced 
in the fibroblasts. Adipogenic differentiation, verified by the 
accumulation of cytoplasmic lipid vacuoles and Oil Red O 
staining, was distinctly observed in the BM- and A-MSCs, 
whereas theCB- and P-MSCs were only weakly positive. Only 
a few or very small Oil Red O-stained granules were detected 
in the fibroblasts, and this could be explained by the findings 
of a previous study which suggested that human dermal fibro-
blasts exhibit delayed adipogenic differentiation compared 
with MSCs (as also shown in Fig. 3A) (20). Chondrogenesis, 
verified by cartilage-specific proteoglycans and Safranin O 
staining, was demonstrated in all the tested cells (Fig. 3B). The 
BM- and A-MSCs exhibited only tri-lineage potency, whereas 
the CB- and P-MSCs had the capacity to differentiate into 
only 2 cell lineages. The fibroblasts also differentiated into 
adipocytes and chondrocytes, although the results were weakly 
positive. Therefore, we suggest that only the BM- and A-MSCs 
can differentiate into 3 mesodermal lineages, i.e., osteoblasts, 
adipocytes and chondrocytes, thus demonstrating that of the 
cells from diverse sources, only the BM- and A-MSCs have 
multipotency as true MSCs.
Subsequently, we evaluated the osteogenic, adipogenic and 
chondrogenic gene expression in the cells by RT-PCR (Fig. 2B). 
Osteogenesis-related gene runt-related transcription 
factor 2 (RUNX2), adipogenesis-related genes peroxisome 
proliferator-activated receptor gamma (PPARG), CCAAT/
enhancer-binding protein alpha (C/EBPA), and chondrogen-
esis-related genes bone morphogenetic protein 7 (BMP7) 
and sex determining region Y-box 9 (SOX9) were similarly 
expressed in the majority of cell types, whereas distal-less 
homeobox 5 (DLX5), which plays a key role in the develop-
ment of skeletal elements and the commitment of MSCs to the 
osteoblast lineage was only expressed in the BM-MSCs and 
A-MSCs. RUNX2 and PPARG expression in the BM-MSCs 
were lower than in the other cell types. These results again 
support our theory that BM- and A-MSCs possess tri-lineage 
differentiation potential.
Table II. Immunophenotyping of cells derived from various sources by flow cytometry.
Surface marker Fibroblasts BM-MSCs CB-MSCs P-MSCs A-MSCs
CD14 1.0±1.5a 1.4±0.8 1.3±0.6 0.8±0.8 2.0±1.1
CD29 82.3±15.6 97.5±1.9 94.4±7.9 98.6±1.9 68.5±17.9
CD31 1.2±0.4 1.8±1.4 1.0±0.9 0.4±0.5 0.6±0.5
CD34 0.8±1.2 2.3±1.6 6.1±8.4 0.7±0.7 1.8±1.1
CD44 93.3±11.7 100±0.0 96.5±6.0 93.0±12.0 99.8±0.3
CD45 0.7±0.6 1.7± 1.5 0.5±0.4 0.4±0.3 0.9±0.4
CD73 99.3±0.3 99.1±0.9 93.7±6.3 99.5±0.8 90.9±3.0
CD90 90.9±10.1 83.1±20.3 66.4±11.2 22.2±12.7 62.5±16.9
CD105 91.7±0.6 90.3±12.1 68.2±27.2 73.5±36.3 75.0±14.1
CD106 1.0±1.6 4.3±1.6 6.3±7.5 0.9±1.1 2.0±1.2
aMeans ± SD of 3 experiments. BM-MSCs, bone marrow-derived mesenchymal stem cells; CB-MSCs, umbilical cord blood-derived mesen-
chymal stem cells; P-MSCs, placenta-derived mesenchymal stem cells; A-MSCs, adipose tissue-derived mesenchymal stem cells.
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DLX5 expression and osteogenic potential. To confirm the 
differential expression of DLX5 and osteogenic potential, 
we performed RT-PCR analysis of DLX5 in various MSCs 
derived from 3 different donors. DLX5 was expressed in all 
assessed BM-MSCs and A-MSCs (Fig. 4A). However, DLX5 
was also detected in 2 out of 3 CB-MSCs (donors 8 and 9) 
and 1 of 3 P-MSCs (donor 10), indicating the heterogeneity of 
MSCs between donors and/or preparations. We analyzed the 
in vitro osteogenic potential of those MSCs tested for DLX5 
gene expression (Fig. 4B). Following osteogenic induction, 
the BM- and A-MSCs from all 3 donors possessed cells with 
an osteogenic phenotype. By contrast, the DLX5-expressing 
CB-MSCs developed an osteogenic phenotype, albeit at 
varying degrees and this coincided with DLX5 expres-
sion (donors 8 and 9). Only a weak osteogenic phenotype was 
observed in one of the DLX5-expressing P-MSCs, and no 
osteogenic phenotype was induced in the fibroblasts. It is clear 
that the levels of DLX5 expression do not necessarily correlate 
with osteogenic potential. The discrepancy in DLX5 expres-
sion and the osteogenic potential of A-MSCs may be explained 
by the differences in the expression of growth factors, growth 
factor receptors and transcription factors involved in osteogen-
esis. Our data suggest that DLX5, one of the key transcription 
factors for osteoblast differentiation, is a predictive marker for 
the osteogenic potential of MSCs. In addition, we noted great 
inter-individual variation in the degree of osteogenic potential 
between the MSCs obtained from different tissues.
Suppression of T cell proliferation by MSCs derived from 
different tissues. To assess the immunomodulatory effects of 
MSCs on activated T cells, we performed a BrdU ELISA assay 
in T cells co-cultured with various MSCs. The proliferation of 
T cells was suppressed by MSCs derived from different tissues 
to varying degrees (Fig. 5A). While the fibroblasts and P-MSCs 
only weakly inhibited the cell proliferation induced by PHA, a 
clear reduction in cell proliferation was observed in the BM- 
and A-MSCs.
It is well known that the immunomodulatory properties 
of MSCs are mediated by HLA and soluble cytokines. The 
expression of HLA-A and HLA-G was readily detectable in 
all tested cells, implying that the expression level of HLA-G 
and MHC class I proteins (HLA-A) in MSCs and fibroblasts 
could not account for the observed inhibition of T cell prolif-
eration (Fig. 5B). Expression of HLA-DRB4 was negative in 
all cells. We then analyzed the gene expression profiles of 
cytokines related to immunomodulation by RT-PCR that 
included interleukin 10 (IL10), TGFB1, tumor necrosis factor, 
alpha-induced protein 6 [(TNFAIP6), tumor TNF-stimulated 
gene 6 (TSG-6)] and interleukin 6 (IL6) (Fig. 5C). The relative 
quantification of gene expression from the MSCs was normal-
Figure 2. Tri-lineage differentiation of mesenchymal stem cells (MSCs) derived from different tissues. (A) In vitro differentiation assay. MSCs were induced 
to differentiate toward osteogenic lineage and verified by von Kossa staining after induction (magnification, x200; scale bar, 100 µm), adipogenic lineage and 
verified by Oil Red O (magnification, x400; scale bar, 50 µm), and chondrogenic lineage and verified by Safranin O staining (magnification, x200; scale bar, 
100 µm). One representative of 3 independent experiments is shown. (B) RT-PCR analysis for tri-lineage differentiation-associated markers in MSCs derived 
from bone marrow (BM-MSCs), umbilical cord blood (CB-MSCs), the placenta (P-MSCs) and adipose tissue (A-MSCs) compared to fibroblasts. The expression 
of osteogenic (DLX5 and RUNX2), adipogenic (PPARG and C/EBPA) and chondrogenic-associated genes (BMP7 and SOX9) was assayed. The expression of 
B4GALNT1 was confined to MSCs, and was not noted in fibroblasts. One representative of 3 independent experiments is shown.
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ized to the internal control, GAPDH. The expression of TGFB1 
was higher in the BM-MSCs when compared with the P-MSCs 
and A-MSCs. Compared to the fibroblasts, no significant differ-
ences were detected in the expression of TNFAIP6 and IL6 in 
Figure 3. (A) Adipogenenic differentiation potential of mesenchymal stem cells (MSCs) derived from different tissue sources. Adipogenic differentiation was carried 
out for MSCs and fibroblasts isolated from different donors and terminated after 21 days. Fibroblast, bone marrow (BM)-, cord blood (CB)-, placental (P)-, adipose 
tissue (A)-derived MSCs from different donors were stained by Oil Red O for intracellular lipid vesicles after induction (x400). (Scale bar, 50 µm). (B) Chondrogenic 
potential of MSCs derived from different tissue sources. Chondrogenic differentiation was induced for 21 days. Fibroblasts, and bone marrow, cord blood, placental, 
and adipose tissue-derived MSCs from different donors were induced and analyzed by Safranin-O staining (x200 magnification). (Scale bar, 100 µm).
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the MSCs derived from different tissues. Notably, a strong 
IL10 expression was observed in the BM-MSCs compared to 
that of fibroblasts and P-MSCs, implying that BM-MSCs exert 
immunosuppressive activity primarily via IL10.
Discussion
Due to their regenerative and immunosuppressive properties, 
MSCs derived from adult tissues have become a preferred cell 
type in the field of regenerative medicine and are being exten-
sively investigated for their clinical applications (21). Although 
bone marrow is considered a universal source of multipotent 
MSCs, the invasive procedure necessary to harvest these cells, 
the risks of complications and the age-dependent decline 
of the self-renewal capacity of MSCs has led to a search for 
alternate sources for MSCs (22,23). CB-MSCs, P-MSCs and 
A-MSCs have been suggested as alternative sources of MSCs 
for experimental and clinical purposes since they are free from 
ethical concerns, easy to procure and are available in large 
quantities (24-26). Currently, BM-, CB-, P- and A-MSCs are 
the representative candidates for stem cell therapy (27). As 
MSCs are being isolated from different tissue sources with 
different protocols of isolation and culture expansion, it is 
unclear whether these MSCs share common properties or are 
dissimilar in terms of certain characteristics that may affect 
their clinical utilization and outcome. Thus, the comparative 
analysis of cellular behaviour in vitro, phenotypes, differen-
tiation potential, and immunosuppressive capacity is useful 
for their potential utilization in clinical settings. In order to 
characterize MSCs derived from various tissue sources in a 
number of parameters, all cell preparations in the present study 
were treated under identical conditions to minimize variables 
that affect cellular characteristics.
The data obtained demonstrated that MSCs derived 
from different tissues and the fibroblasts (used as controls) 
exhibited a similar morphology, clonogenic capacity and 
immunophenotype, but differed in terms of proliferative rates 
and differentiation potential. The P-MSCs consistently grew 
faster and more robustly than the cells derived from other 
tissues, with a rapid population doubling time. MSCs have a 
limited life span and enter replicative senescence during in vitro 
culture, as indicated by enlarged and irregular cell shapes and 
cessation of proliferation (28). The BM-, CB- and A-MSCs 
exhibited replicative senescence when they reached passage 10 
on average, whereas the P-MSCs expanded until passage 15. 
Thus, MSCs are theoretically capable of long-term culture 
in vitro without losing their fundamental stem cell properties; 
however, we noted that the growth capacity of the MSCs was 
Figure 4. Correlation of DLX5 and osteogenic differentiation capacity of various mesenchymal stem cells (MSCs) from multiple donors. (A) DLX5 transcript 
of 3 different donors for each MSC derived from different tissues was amplified by RT-PCR. (B) Histologic appearance with von Kossa staining of MSCs of 
the 3 donors used for RT-PCR in (A). While bone marrow (BM)-derived MSCs and adipose tissue-derived MSCs (A-MSCs) exhibited prominent osteogenic 
phenotypes, MSCs derived from cord blood and the placenta exhibited inter-donor variation in osteogenic differentiation. (Scale bar, 100 µm).
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generally inferior to that of fibroblasts. Our results demonsrated 
that P-MSCs are superior to the other MSC types with regard 
to growth, but more CFU-F colonies were observed among the 
BM- and CB-MSCs. These results suggest that rapid and long-
term growth is not required for the ‘stem’ properties of MSCs.
Although a list of surface molecules was proposed by 
ISCT as one of the minimal criteria for MSC identification, 
all tested markers did not distinguish MSCs from fibroblasts. 
Thus, the identification of a single definitive marker and 
precise characterization of MSCs derived from various tissues 
with regard to their multipotency will be a significant advance 
for their clinical application. In our phenotypic analysis, we 
noted that MSCs derived from various sources were positive 
for the expression of the MSC markers, CD44, CD73, CD90, 
and CD105, and were negative for CD14, CD34 and CD45. 
However, CD90 expression, which is known to be associated 
with haematopoiesis and cell migration, was slightly different 
among the P-MSCs, and its biological significance needs 
to be determined. As the function of MSCs is governed by 
differential molecular profiles, we analyzed the expression 
of pluripotency genes in order to provide further insight into 
the differences between MSCs from different tissues. In this 
study, SOX2, which is involved in self-renewal in pluripotent 
stem cells and multipotency in MSCs, was only expressed in 
BM-MSCs, implying the more primitive status of BM-MSCs, 
as has also been previously noted (29). Since SOX2 functions 
as a molecular switch in neuronal development, its expres-
sion in BM-MSCs may reflect the neuronal differentiation 
potential (30). BM-MSCs expressed detectable amounts of the 
majority of core transcription factors, as evidenced by RT-PCR, 
such as SOX2, MYC, KLF4 and NANOG, even in the absence 
of exogenous stimuli, whereas A-MSCs expressed MYC, KLF4, 
NANOG, LIN28 and REX1. The amplified transcripts were of 
the same size as those in human iPS cells. It was previously 
demonstrated that INHBA is required for the chondrogenic and 
osteogenic differentiation of MSCs (31), and our data indicated 
that the BM- and A-MSCs exhibited a higher expression of 
INHBA than the other MSCs. Thus, these data demonstrate 
that BM- and A-MSCs have properties of primitive multipotent 
stem cells. KLF4 was ubiquitously expressed in MSCs, as well 
as fibroblasts.
It is well known that MSCs possess immunosuppres-
sive properties and can inhibit the proliferation and function 
of major immune cell populations, including T cells (32). In 
the present study, in activated T cell co-cultures with MSCs 
in vitro, only the BM- and A-MSCs significantly inhibited 
T cell proliferation induced by PHA. While HLA-G expression 
is known to be involved in the immunomodulation induced 
by MSCs, we also found that all MSCs and fibroblasts were 
positive for HLA-A and HLA-G, and negative for HLA-DRB4 
Figure 5. Immunomodulatory effects of mesenchymal stem cells (MSCs) derived from various sources on activated T cells co-cultured with MSCs. (A) Suppression 
of human peripheral blood mononuclear cells (MNCs) by MSCs. Proliferation of MNCs (2x105 cells) co-cultured with MSCs (2x104 cells) from different tissues 
in the presence of 10 µg/ml of phytohaemagglutinin (PHA) for 72 h was evaluated by BrdU ELISA. The data represent the means ± SD of 3 experiments; *p<0.05. 
(B) Gene expression of HLA-A, HLA-DRB4 and HLA-G for immunomodulation in cells derived from various sources. (C) Relative mRNA expression levels of 
immunosuppressive RT-PCR of interleukin 10 (IL10), transforming growth factor beta 1 (TGFB1), tumor necrosis factor, alpha-induced protein 6 (TNFAIP6) 
and IL6 in MSCs from different tissues. Expression levels relative to those of the housekeeping gene, GAPDH are shown. The data represent the means ± SD of 
3 experiments; *p<0.05.
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(as shown by RT-PCR), indicating that the expression of HLA 
molecules is not associated with the inhibitory capacity of 
PHA-induced T cell proliferation (33,34). However, the possible 
involvement of HLA-G in the immunosuppression of MSCs via 
other immune cells cannot be excluded. Other factors associ-
ated with the immunomodulatory effects of MSCs include 
IL10, TGFB1, IL6 and TNFAIP6, TSG-6 (35,36). In the present 
study, BM-MSCs displayed the greatest suppressive effects 
on T cells, and elevated levels of IL10 and TGFB1 were noted 
in the BM-MSCs compared to the other MSCs and the fibro-
blasts, and this is in agreement with the findings of previous 
studies (37-39).
Concerning the multipotency of MSCs derived from 
different tissues, their multilineage differentiation capacity was 
confirmed by in vitro differentiation into osteoblasts, adipocytes 
and chondrocytes. All of the cells had differentiation potential 
for at least 2 lineages. In our study, fibroblasts also differenti-
ated toward adipocyte and chondrocyte lineages, as has also 
been reported previously (20). Only the BM- and A-MSCs 
differentiated into 3 lineages, including osteoblasts. To identify 
functional regulator(s) that govern the differentiation potential 
of MSCs into a specific lineage, we selected 6 genes that are 
known to play key roles in mesodermal lineage differentiation 
and verified that only DLX5 is differentially expressed in MSCs 
with osteogenic potential. Our findings suggest that only BM- 
and A-MSCs have tri-lineage differentiation potential and thus 
meet the minimal criteria for an MSC, as defined by the ISCT. 
We also demonstrated that B4GALNT1 (GM2/GS2 synthase), 
the neural ganglioside GD2 synthase, is expressed by MSCs 
derived from different tissues. This finding is consistent with 
the findings of Martinez et al, that GD2 is a valuable marker 
that uniquely distinguishes MSCs from fibroblasts (40).
DLX5, one of the mammalian homologs of the Drosophila 
Distal-less (DLL/DLX) genes, is a homeodomain transcrip-
tion factor that regulates the development of multiple cell 
types, including osteoblasts and neural cells (41,42). Since 
DLX5 expression has the potential to identify cells with 
lineage-specific differentiation capacity, in the present study 
this was further evaluated in MSCs from multiple donors. In 
all donors tested, DLX5 was expressed in MSCs with dominant 
osteogenic potential, i.e., BM- and A-MSCs. By contrast, 2 of 
3 donors of CB-MSC and 1 of 3 donors of P-MSCs expressed 
DLX5, and the same donors exhibited a concurrent osteogenic 
phenotype, albeit to varying degrees. Thus, the osteogenic 
potential of MSCs, regardless of their tissue origin, appears to 
be related to DLX5 expression. To the best of our knowledge, 
this is the first study that suggests that DLX5 expression is a 
predictive maker for MSCs with osteogenic potential. However, 
it remains to be determined, using a larger number of donors, 
whether DLX5 expression firmly characterizes a subset of 
MSCs with osteogenic potential, although studies of inter-
donor variation with regard to growth rate, marker expression 
and multipotency have already been undertaken (43,44).
Our finding of the variation in DLX5 expression between 
MSCs adds further support to the accumulating evidence that 
points to substantial diversity both within and between MSCs 
from various tissue sources (45-47), although little is known 
regarding the functional differences between MSCs from 
different tissue and/or different donors. Differences in donor 
age, gender, genetics, epigenetics and environmental factors 
have been postulated as the basis for this heterogeneity (48). 
The issue of MSC heterogeneity has profound implications for 
clinical application of MSCs, such as establishing standardized 
protocols that can generate functionally equivalent cellular 
therapeutics (49,50). Thus, the characterization of MSCs 
derived from various tissues with standardized protocols will 
have a great impact on clinical outcomes, such as homing, 
repairing and/or regenerating damaged tissues.
In conclusion, in this study, we demonstrated that there are 
significant differences in the characteristics of MSCs derived 
from various tissue sources and fibroblasts (used as controls), 
including their multipotency, stemness signature and lineage 
associated markers. Specifically, the BM- and A-MSCs exhib-
ited full tri-lineage (osteogenic, adipogenic and chondrogenic) 
differentiation potential, and this ability was associated with 
the expression of DLX5. In addition, there was a donor-related 
variation of osteogenic potential in the CB- and P-MSCs, and 
this potential appeared to be associated with DLX5 expression. 
In conclusion, the findings of this comparative study contribute 
to the development of MSC-based cell therapies and regenera-
tive medicine by providing valuable information which can be 
used when selecting the optimal MSCs for specified clinical 
applications.
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